Overview of studies of the vitamin D/vitamin D receptor system in the development of non-alcoholic fatty liver disease.
World J Gastrointest Pathophysiol. 2019 Sep 10;10(2):11-16. doi: 10.4291/wjgp.v10.i2.11.
Cimini FA1, Barchetta I1, Carotti S2, Morini S3, Cavallo MG1.
- 1 Department of Experimental Medicine, Sapienza University of Rome, Rome I-00161, Italy.
- 2 Department of Medicine and Surgery, Laboratory of Microscopic and Ultrastructural Anatomy, University Campus Bio-Medico of Rome, Rome I-00128, Italy.
- 3 Department of Medicine and Surgery, Laboratory of Microscopic and Ultrastructural Anatomy, University Campus Bio-Medico of Rome, Rome I-00128, Italy, s.morini at unicampus.it.
Items in both categories Liver and Vitamin D Receptor are listed here:
- Liver Cirrhosis death is 4X more likely if poor Vitamin D Receptor – Sept 2018
- Non-alcoholic fatty liver disease and the Vitamin D Receptor – editorial Sept 2019
- Hepatitis B virus reduced by 5X the Vitamin D getting to liver cells in the lab – Oct 2018
- Perhaps a sunshine option for chronic liver disease – Nov 2013
- Liver and interactions with vitamin D deficiency - Review July 2013
Vitamin D Receptor category has the following
Vitamin D tests cannot detect Vitamin D Receptor (VDR) problems
A poor VDR restricts Vitamin D from getting in the cells
It appears that 30% of the population have a poor VDR (40% of the Obese )
VDR at-home test $29 - results not easily understood in 2016
There are hints that you may have inherited a poor VDR
Compensate for poor VDR by increasing one or more:
|1) Vitamin D supplement|
Sun, Ultraviolet -B
| Vitamin D in the blood |
and thus in the cells
|2) Magnesium||Vitamin D in the blood |
AND in the cells
|3) Omega-3||Vitamin D in the cells|
|4) Resveratrol||Vitamin D Receptor|
|5) Intense exercise||Vitamin D Receptor|
|6) Get prescription for VDR activator|
|Vitamin D Receptor|
|7) Quercetin (flavonoid)||Vitamin D Receptor|
|8) Zinc is in the VDR||Vitamin D Receptor|
|9) Boron||Vitamin D Receptor ?, |
|10) Essential oils e.g. ginger, curcumin||Vitamin D Receptor|
|11) Progesterone||Vitamin D Receptor|
|12) Infrequent high concentration Vitamin D|
Increases the concentration gradient
|Vitamin D in the cells|
|13) Sulfroaphane and perhaps sulfur||Vitamin D Receptor|
Note: If you are not feeling enough benefit from Vitamin D, you might try increasing VDR activation. You might feel the benefit within days of adding one or more of the above
Far healthier and stronger at age 72 due to supplements Includes 6 supplements that help the VDR
Items in both categories Liver and Intervention are listed here: give vitamin D and see what happens
- NAFLD is treated by Vitamin D, Omega-3, Curcumin, Silymarinm, etc. Aug 2018
- Alcoholic liver cirrhosis treated by 1,000 IU of vitamin D – July 2018
- Severe Non-Alcoholic fatty liver disease treated by Omega-3 – RCT April 2018
- Weekly dosing of vitamin D is far better than single large dose (chronic liver, children) – March 2018
- Fatty liver disease in children nicely treated by combination of Vitamin D and Omega-3 – RCT Dec 2016
- Non-Alcoholic Fatty Liver Disease (NAFLD) treated by Vitamin D (20,000 IU weekly after loading dose) – RCT June 2016
- Non-alcoholic fatty liver disease (NAFLD) reduced somewhat by 50,000 IU vitamin D every 2 weeks – RCT Sept 2014
- 400,000 IU barely raised liver transplant candidate vitamin D levels (no surprise) – March 2015
- Vitamin D prevents Hepatitis-C and helps treat it (many studies)
Items in both categories Liver and Meta-analysis are listed here: summary of trials
- NAFLD associated with low vitamin D (in children too) – meta-analysis Aug 2019
- Hepatitis B patients have 2 ng lower level of Vitamin D – meta-analysis June 2019
- Non-Alcoholic Fatty Liver Disease treated by Omega-3 – three meta-analysis 2016-2017
- Fatty liver disease weakly associated with low vitamin D – meta-analysis 2013
- Strong association of non alcoholic fatty liver disease and low vitamin D
- Non-alcoholic Fatty Liver Disease (4 in 10 seniors) and Vitamin D
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world. NAFLD is known to be associated with obesity, type 2 diabetes, metabolic syndrome and increased cardiovascular events: for these reasons, it is becoming a global public health problem and represents an important challenge in terms of prevention and treatment. The mechanisms behind the pathogenesis of NAFLD are multiple and have not yet been completely unraveled; consequently, at moment there are not effective treatments. In the past few years a large body of evidence has been assembled that attributes an important role in hepatic aberrant fat accumulation, inflammation and fibrosis, to the vitamin D/vitamin D receptor (VD/VDR) axis, showing a strong association between hypovitaminosis D and the diagnosis of NAFLD. However, the data currently available, including clinical trials with VD supplementation, still provides a contrasting picture.
The purpose of this editorial is to provide an overview of recent advances in the pathogenesis of NAFLD in relation to VD/VDR. Based on recent data from literature, we focused in particular on the hypothesis that VDR itself, independently from its traditional ligand VD, may have a crucial function in promoting hepatic fat accumulation. This might also offer new possibilities for future innovative therapeutic approaches in the management of NAFLD.
|1238 visitors, last modified 29 Sep, 2019,